<DOC>
	<DOCNO>NCT01410344</DOCNO>
	<brief_summary>The rationale trial demonstrate feasibility safety allogeneic HCT patient chemotherapy-sensitive hematological malignancy coincident HIV-infection . In particular , trial focus 100-day non-relapse mortality indicator safety transplant patient population . Correlative assay focus upon incidence infectious complication patient population , evolution HIV infection immunological reconstitution . Where feasible ( accomplish without compromise either donor quality timeliness transplantation ) , attempt make identify donor homozygotes delta32 mutation CCR5 .</brief_summary>
	<brief_title>Allogeneic Transplant HIV Patients ( BMT CTN 0903 )</brief_title>
	<detailed_description>The study design evaluate feasibility safety reduced-intensity fully-ablative allogeneic hematopoietic cell transplantation ( HCT ) patient hematological malignancy myelodysplastic syndrome ( MDS ) HIV infection . The goal study assess 100 day Non-relapse Mortality well immunological reconstitution patient population . Where feasible , attempt make identify human leukocyte antigen ( HLA ) -compatible hematopoietic stem cell donor homozygotes delta32 mutation chemokine receptor 5 ( CCR5delta32 ) . Patients undergo treatment plan review prior registration trial . All patient undergo allogeneic HCT match sibling unrelated donor .</detailed_description>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<criteria>1 . HIV1 infection , document rapid HIV test FDAApproved HIV1 Enzyme Chemiluminescence Immunoassay ( E/CIA ) test kit confirm Western Blot time prior study entry . HIV antigen , plasma HIV1 RNA , secondary antibody test method rapid HIV E/CIA acceptable alternative test . Alternatively , rapid HIV test FDAApproved HIV1 Enzyme Chemiluminescence Immunoassay ( E/CIA ) test available , two HIV1 RNA value ≥ 2000 copies/mL least 24 hour apart perform laboratory CLIA certification , equivalent , may use document infection . 2 . Patients must willing comply effective Antiretroviral Therapy . 3 . Patients must ≥ 15 year age . 4 . Hematological malignancy associate poor prognosis medical therapy alone . Diagnoses include : 1 . Patients diagnosis Acute Myeloid Lymphocytic Leukemia ( AML ALL ) first second complete remission . 2 . Patients advance myelodysplastic syndrome ( MDS ) , include International Prognostic Scoring System ( IPSS ) Int2 highrisk disease le 10 % marrow blast circulate myeloblast recent therapy . Patients acute leukemia develops preexist MDS must meet inclusion criterion patient AML detail . 3 . Hodgkin Lymphoma beyond first remission achieve least partial response recent therapy evidence progression prior transplant . 4 . NonHodgkin Lymphoma beyond first remission achieve least partial response recent therapy evidence progression prior transplant . 5 . Donor/Recipient HLA Matching : 1 . Related donor : must 8/8 match HLAA , B , C , ( serologic type high resolution ) DRB1 ( high resolution use DNA base typing ) . A 7/8 related donor match permit 8/8 unrelated donor identify . 2 . Unrelated donor : must 7/8 8/8 match HLAA , B , C , DRB1 ( high resolution use DNA base typing ) . 6 . Patients adequate organ function measure : 1 . Cardiac : Left ventricular ejection fraction rest ≥ 40 % demonstrate Multi Gated Acquisition Scan ( MUGA ) echocardiogram . Patients know heart disease must functional status bad American Heart Association Class I define patient cardiac disease without result limitation physical activity . Ordinary physical activity cause undue fatigue , palpitation , dyspnea , anginal pain . 2 . Hepatic : . Total Bilirubin &lt; 2.0 mg/dL ( except isolate hyperbilirubinemia attribute Gilbert syndrome antiretroviral therapy specify Appendix E ) alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) &lt; 5x upper limit normal . ii . Concomitant Hepatitis : Patients chronic hepatitis B C may enrol trial provide bilirubin transaminase criterion meet . In addition , must clinical pathologic evidence irreversible chronic liver disease , must active viral replication evidence undetectable hepatitis viral load PCRbased assay . c ) Renal : Creatinine clearance ( calculated creatinine clearance permit ) &gt; 40 mL/min . ) Pulmonary : Diffusing capacity lung carbon monoxide ( DLCO ) , forced expiratory volume one second ( FEV1 ) , force vital capacity ( FVC ) ≥ 45 % predict ( correct hemoglobin ) . 7 . Signed Informed Consent 1 . Karnofsky/Lansky performance score &lt; 70 % . 2 . Active central nervous system ( CNS ) malignancy ; however , patient history positive Cerebrospinal fluid ( CSF ) cytology become negative intrathecal chemotherapy eligible . 3 . Uncontrolled bacterial , viral fungal infection ( currently take medication progression clinical improvement ) . 4 . Active Cytomegalovirus ( CMV ) retinitis CMVrelated organ dysfunction . 5 . AIDS relate syndrome symptom pose perceive excessive risk transplantationrelated morbidity determine principal investigator . 6 . Untreatable HIV infection due multidrug antiretroviral resistance . Patients detectable viral load &gt; 750 copies/ml evaluate HIV drug resistance test ( HIV1 genotype ) . The result include part Antiretroviral Review ( describe Appendix D ) . This Review Committee make final determination whether HIV viremia could potentially suppress alternate antiretroviral therapy . . 7 . Pregnant ( positive βHCG ) breastfeeding . 8 . Fertile men woman unwilling use contraceptive technique time initiation mobilization sixmonths posttransplant . 9 . Prior allogeneic HCT . 10 . Patients psychosocial condition would prevent study compliance followup , determine principal investigator . 11 . Tcell depletion ( include ATG alemtuzumab ) allow . 12 . Use cord blood source hematopoietic cell allow .</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>HIV</keyword>
	<keyword>ALL</keyword>
	<keyword>AML</keyword>
	<keyword>MDS</keyword>
	<keyword>Non-Hodgkin Lymphoma</keyword>
</DOC>